TRVX Targovax AS

Edison Investment Research Limited: Edison issues update on Targovax (TRVX)

Edison Investment Research Limited
Edison Investment Research Limited: Edison issues update on Targovax (TRVX)

22-Jun-2020 / 17:42 GMT/BST

 

London, UK, 22 June 2020

Edison issues update on Targovax (TRVX)

On 22 June 2020 Targovax reported data from its Phase I/II study in unresectable mesothelioma (a follow up to the first data published in January 2020). There were no new safety issues and the efficacy signals seen in the first set of data were confirmed. Importantly, the immune and gene sequencing data provided strong support for ONCOS-102's ability to activate the immune system and remodel the tumour microenvironment. Targovax reiterated its plans to explore ONCOS-102 in triple combination with a checkpoint inhibitor (CPI) and standard chemotherapy in first line. These plans are still at a preliminary stage, but there is potential for the study to become a registrational programme due to a high unmet need in mesothelioma. We increase the probability of success for ONCOS-102 and our updated valuation is NOK1.64bn or NOK21.6/share.

 

Our valuation has increased to NOK1.64bn or NOK21.6/share from NOK1.52bn or NOK20.0/share after increasing the success probability in our mesothelioma project to 25% from 20% and rolling the model forward. An update on the upcoming Phase I melanoma trial is the key potential catalyst this year.


to view the full report.

 

All reports published by Edison are available to download free of charge from its website

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the .

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Jonas Peciulis, +44 (0)20 3077 5728

 

Learn more at and connect with Edison on: 

LinkedIn       

Twitter          

YouTube      


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service

1076019  22-Jun-2020 

fncls.ssp?fn=show_t_gif&application_id=1076019&application_name=news&site_id=research_pool
EN
22/06/2020

Underlying

TRVXTargovax AS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Targovax AS

Geir Hiller Holom
  • Geir Hiller Holom
Free Trial
TRVX TARGOVAX AS

Circio Holding (No_rec, TP: NOK) - circVec circular RNA technology

Yesterday, Circio Holding presented the circVec platform and its potential at two international industry conferences. We continue to like the focus on the circRNA programme, but the company is still in an early stage and the funding situation remains unclear to us.

03/06/25 March 6, 2025 1 EN
Geir Hiller Holom
  • Geir Hiller Holom
Free Trial
TRVX TARGOVAX AS

Circio Holding (No_rec, TP: NOK) - Development continues, financing un...

We continue to believe Circio’s technology has significant potential and that the company will successfully secure a partnering deal. However, while we estimate it has secured a runway through H1 2025, the funding situation remains unclear to us, and we thus continue to have no recommendation or target price on Circio.

09/30/24 September 30, 2024 1 EN
Geir Hiller Holom
  • Geir Hiller Holom
Free Trial
TRVX TARGOVAX AS

Circio Holding (No_rec, TP: NOK) - Recommendation and target price wit...

We continue to like Circio’s focus on the circRNA programme and believe it will be able to secure a partnering deal in 2025. However, the funding situation is unclear. It recently announced an intention to raise cNOK50m–60m in Q2. As we have limited input on the terms of the upcoming capital raise and Atlas Capital Markets’ (the counterparty of the convertible bond facility announced in February 2023) degree of participation and conditions, we have withdrawn our target price and recommendation.

05/10/24 May 10, 2024 1 EN
Frank Maaø ... (+9)
  • Frank Maaø
  • Geir Hiller Holom
  • Joachim Gunell
  • Jonatan Andersson
  • Jørgen Lian
  • Martin Arnell
  • Niclas Gehin
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
ERIC B TELEFONAKTIEBOLAGET LM ERICSSON CLASS B
SBL SAFE BULKERS INC.
GNK GENCO SHIPPING & TRADING LTD.
GN GN STORE NORD A/S
TOM TOMRA SYSTEMS ASA
MTG B MODERN TIMES GROUP MTG AB CLASS B
SBLK STAR BULK CARRIERS CORP.
GOGLO GOLDEN OCEAN GROUP LTD
TRVX TARGOVAX AS
ENEA ENEA AB
2020 2020 BULKERS LTD
EGLE EAGLE BULK SHIPPING
VEFAB VEF
SUS SURGICAL SCIENCE SWEDEN AB
04/20/23 April 20, 2023 1 EN
Geir Hiller Holom
  • Geir Hiller Holom
Free Trial
TRVX TARGOVAX AS

Targovax (Buy, TP: NOK4.00) - Rebrand to Circio

Targovax announced its intention to rebrand as Circio to reflect its strategic shift to focus on further development of its proprietary and innovative circular RNA platform. Subject to shareholder approval, Circio Holding ASA will assume the Targovax ASA listing on Oslo stock exchange under the ticker CRNA.

04/19/23 April 19, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch